Posts tagged Tim Lugo
WB ups Akari Therapeutics to OP

William Blair upgraded Akari Therapeutics (NASDAQ:AKTX) to “outperform” from “market perform” after the company announced that, following its end-of-Phase-2 meeting with the FDA, it is advancing Coversin for the treatment of paroxysmal nocturnal hemoglobinuria into two Phase 3 trials - ASSET and CAPSTONE - both of which are set to begin during the first quarter of 2018.

Read More
WB starts Ovid at OP

William Blair initiated coverage of Ovid Therapeutics (NASDAQ:OVID) with an “outperform” rating and fair value estimate of $28. The stock closed at $14.57 on May 26.

Read More
WB starts Biohaven at OP

William Blair launched coverage of Biohaven Pharmaceutical Holding (NYSE:BHVN) with an “outperform” rating and fair value estimate of $46. The stock closed at $23.79 on May 26.

Read More
WB starts Akari Therapeutics at OP

William Blair launched coverage of Akari Therapeutics (NASDAQ:AKTX) with an “outperform” rating. The stock closed at $11.62 on April 5.

Read More
WB starts Collegium Pharma at outperform

William Blair & Co. has initiated coverage of Collegium Pharmaceutical (NASDAQ:COLL) with an “outperform” rating and price target of $35. The stock closed at $19.25 on Thursday.

Collegium’s lead product, Xtampza ER, an extended-release oxycodone-based product with abuse-deterrent technology (ADT), has received tentative approval from the FDA for the treatment of chronic pain that requires around-the-clock opioid analgesia for an extended period.

Read More